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Abstract
Background We investigated whether genes influencing
coagulation are associated with the occurrence of aneurysmal
subarachnoid hemorrhage (SAH) and with secondary cerebral
ischemia and rebleeding in patients with aneurysmal SAH.
Method Genotyping for factor V Leiden (G1691A), pro-
thrombin G20210A, methylenetetetrahydrofolate reductase
(MTHFR) C677T, factor XIII subunit AVal34Leu, Tyr204Phe
and Pro564Leu, and factor XIII subunit B His95Arg was
performed in 208 patients with aneurysmal SAH and in 925
controls. Secondary cerebral ischemia occurred in 49 (24%)
patients and rebleeding in 28 (14%) during their clinical
course of 3 months after the aneurysmal SAH. The risk of
aneurysmal SAH was assessed as odds ratio (OR) with 95%
confidence interval (95% CI). The risk of secondary cerebral
ischemia and rebleeding was assessed as hazard ratio (HR)
with 95% CI using Cox regression.
Findings Carriers of the subunit B His95Arg factor XIII
polymorphism had an increased risk of aneurysmal SAH
with 23% of the patients homozygous or heterozygous for
the variant allele compared to 17% of control subjects
(OR 1.5, 95% CI 1.0–2.2). For the remaining genetic
variants no effect on the risk of aneurysmal SAH could be
demonstrated. A clear relation with the risk of secondary
cerebral ischemia and of rebleeding could not be established
for any of the genetic variants.
Conclusions We found that aneurysmal SAH patients are
more often carriers of the subunit B His95Arg factor XIII
polymorphism compared to controls. This suggests that
carriers of the subunit B His95Arg factor XIII polymorphism
have an increased risk of aneurysmal SAH. Larger studies
should confirm our results. As aneurysmal SAH patients who
died soon after admission could not be included in the present
study, our results only apply to a population of patients who
survived the initial hours after the hemorrhage. For the other
studied genetic factors involved in coagulation, no association
with the occurrence of aneurysmal SAH or with the
occurrence of secondary cerebral ischemia or rebleeding after
aneurysmal SAH could be demonstrated.
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Introduction
Spontaneous subarachnoid hemorrhage (SAH) from rupture
of an intracranial saccular aneurysm has an incidence of
approximately 8 per 100,000 [20]. The prognosis after
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aneurysmal SAH is poor with a case fatality rate of 32 to
67% [15]. In patients who survive the initial hours after
aneurysmal SAH, secondary cerebral ischemia and rebleeding
are major causes of death and disability [4, 6, 25]. Secondary
cerebral ischemia occurs in approximately 25% to 35% of
patients [4, 6, 25] during the clinical course. Rebleeding
within the first 4 weeks occurs in 40% if the aneurysm is not
treated [6] and remains an important cause of death, even if
the aim is to occlude the aneurysm early after the bleeding
[27].
Coagulation factors may be involved in aneurysmal
SAH and its subsequent complications. The causes of SAH
without a detectable aneurysm include bleeding disorders,
but the role of coagulation disorders in the occurrence of
aneurysmal SAH is not yet known [26]. A possible higher
risk of aneurysmal SAH has been suggested for a
coagulation factor XIII subunit ATyr204Phe polymorphism
[24]. Studies with antifibrinolytic drugs in patients with
SAH found that this treatment reduces the occurrence of
rebleeding but increases the risk of secondary cerebral
ischemia [14, 28]. Thus, antifibrinolytic drugs have an
opposite effect on the risks of rebleeding and secondary
cerebral ischemia.
A direct analysis of coagulation factors in SAH patients
is hampered by early activation of the coagulation and
fibrinolytic system following the hemorrhage [21]. Therefore,
studying genetic factors may be a better approach to
investigate the role of coagulation factors in the development
of complications after SAH. A genetic study in SAH patients
already suggested that the plasminogen activator inhibitor-1
(PAI-1) gene influencing coagulation is indeed involved in
the occurrence of secondary cerebral ischemia [30]. The role
of polymorphisms in coagulation factor V [5], prothrombin
[22], methylenetetetrahydrofolate reductase (MTHFR, 9),
coagulation factor XIII subunit A [2, 3] and subunit B [18]
genes is currently unclear. The factor V Leiden and
prothrombin G20210A polymorphisms are associated with
an increased risk of thrombosis [5, 22], and for the factor V
Leiden a decreased risk of bleeding has also been
demonstrated [7, 19]. The factor V Leiden and prothrombin
G20210A polymorphisms may therefore be associated with a
possible decreased risk of SAH, an increased risk of
secondary cerebral ischemia and possibly a decreased risk
of rebleeding in SAH patients. In contrast, subunit A
Val34Leu, Tyr204Phe and Pro564Leu factor XIII poly-
morphisms are associated with an increased risk of bleeding
[2, 3] and may increase the risk for aneurysmal SAH and its
subsequent rebleeding, and possibly show a decreased risk of
secondary cerebral ischemia in SAH patients. The role of the
MTHFR C677T polymorphism and subunit B His95Arg
factor XIII polymorphism in coagulation is not (yet) clear
[9, 18], but some studies have found an increased risk of
thrombosis for both variants [17, 18].
The aim of this study was to investigate whether the
above-mentioned polymorphisms are associated with the
occurrence of aneurysmal SAH and with secondary cerebral
ischemia and rebleeding in patients with aneurysmal SAH.
Methods and materials
Patient and control recruitment
Two hundred eight Dutch patients with aneurysmal SAH
admitted to the University Medical Centre Utrecht were
included. Aneurysmal SAH was defined by symptoms
suggestive of SAH combined with evidence of subarachnoid
blood on CT and a proven aneurysm on CT angiography or
conventional angiography. A population-based control group
was used including 925 women aged 18-49 years without a
history of coronary heart disease, cerebrovascular event or
peripheral vascular disease, as described in detail elsewhere
[29]. The ethical review board of the University Medical
Centre Utrecht approved our study protocol.
Data collection
The patient’s age at the time of SAH, sex, clinical condition
on admission, amount of blood on initial CT scan, and any
episodes of rebleeding or secondary cerebral ischemia were
recorded. For the clinical condition on admission the World
Federation of Neurological Surgeons’ (WFNS) scale was
used [8]. The amount of blood on the CT scan on admission
(within 72 h after the initial symptoms) was graded on a
scale of 0 to 30 as defined by Hijdra et al. [11]. Rebleeding
was defined as a sudden deterioration in the level of
consciousness or a sudden increase in headache, combined
with an increase of blood on CT compared with the
previous CT. Secondary cerebral ischemia was defined as
a gradual decline in the level of consciousness or a gradual
development of new focal deficits or both, with confirmation
of a new hypodensity on CT. The patients were followed up
for 3 months.
Laboratory analyses
DNA was isolated from whole venous blood. Genotyping
was performed using polymerase chain reaction (PCR)
using previously described primers and assay conditions for
the factor V Leiden (factor V G1691A) [5], prothrombin
G20210A [22], MTHFR C677T [9], subunit A Val34Leu
[16], Tyr204Phe and Pro564Leu factor XIII [24] and
subunit B His95Arg factor XIII [18] polymorphisms.
Genotyping of the variants was performed on coded DNA
samples so that the patients’ characteristics remained
unknown to the technician.
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Data analyses
The risk of aneurysmal SAH was assessed as an odds ratio
(OR) with corresponding 95% confidence intervals (CI).
The risk of secondary cerebral ischemia and rebleeding was
assessed as a hazard ratio (HR) with 95% confidence
intervals (CI) using Cox regression. For both analyses,
patients homozygous for the wild-type allele were compared
with patients homozygous and heterozygous for the variant
allele. Only for the MTHFR C677T polymorphism patients
homozygous for the variant allele were compared with
patients homozygous for the wild-type allele and heterozygous
for the variant allele, as customary. For the assessment of the
risk of secondary cerebral ischemia patients were censored in
case they had a rebleeding or in case they died. Patients were
censored in the analysis on the risk of rebleeding in case the
aneurysm was treated by means of clipping or coiling or in
case they died. The clinical condition on admission was
determined as ‘good’ (WFNS I-III) or ‘poor’ (WFNS IV-V).
For the amount of cisternal blood, the scores were dichoto-
mized at the median of the Hijdra scores. As a poor clinical
condition on admission and a large amount of extravasated
blood increase the risk of secondary cerebral ischemia [1, 12,
23], we adjusted for these prognostic factors using their
dichotomized values.
Results
The patients’ characteristics are summarized in Table 1. The
mean age was 59.5 years (SD 14.9 years), and 71.6% were
women. Secondary cerebral ischemia occurred in 49 (24%)
patients and rebleeding in 28 (14%).
The ORs for the risk of aneurysmal SAH according to
genotype are shown in Table 2. For carriers of the subunit B
His95Arg factor XIII polymorphism, an increased risk of
aneurysmal SAH was found with 23% of the patients
homozygous and heterozygous for the variant allele
compared to 17% of control subjects (OR 1.5, 95% CI
1.0–2.2, p-value 0.04). Also, carriers of the prothrombin
Table 1 Patients’ baseline characteristics
Characteristics All patients
(n=208)
Mean age ± SD 59.5±14.9
Women 149 (71.6%)
Poor clinical condition on admission 41 (19.7%)
Amount of cisternal blood > median
of the Hijdra score
74 (35.6%)
Rebleeding 28 (13.5%)
Secondary cerebral ischemia 49 (23.6%)
SD = standard deviation
Genotype Patients* Controls** Odds ratio (95% CI)
FV Leiden n=207 n=763
GG 196 (94.7%) 721 (94.5%) 1 (reference)
GA and AA 11 (5.3%) 42 (5.5%) 0.9 (0.5–1.8)
Prothrombin G20210A n=207 n=763
GG 200 (96.6%) 745 (97.6%) 1 (reference)
GA and AA 7 (3.4%) 18 (2.4%) 1.5 (0.6–3.5)
MTHFR C677T n=207 n=764
CC and CT 185 (89.4%) 695 (91.0%) 1 (reference)
TT 22 (10.6%) 69 (9.0%) 1.2 (0.3–2.0)
FXIII A Val34Leu n=208 n=747
ValVal 122 (58.7%) 419 (56.1%) 1 (reference)
ValLeu and LeuLeu 86 (41.3%) 328 (43.9%) 0.9 (0.7–1.2)
FXIII A Tyr204Phe n=207 n=754
TyrTyr 188 (90.8%) 711 (94.3%) 1 (reference)
TyrPhe and PhePhe 19 (9.2%) 43 (5.7%) 1.7 (0.9–2.9)
FXIII A Pro564Leu n=194 n=751
ProPro 114 (58.8%) 466 (62.0%) 1 (reference)
ProLeu and LeuLeu 80 (41.2%) 285 (38.0%) 1.2 (0.8–1.6)
FXIII B His95Arg n=196 n=730
HisHis 151 (77.0%) 609 (83.4%) 1 (reference)
HisArg and ArgArg 45 (23.0%) 121 (16.6%) 1.5 (1.0–2.2)




*For the genotype analysis of
the patients the percentage of
missing genotypes is 2%
**For the genotype analysis of
the controls the percentage of
missing genotypes is 18%
CI = confidence interval
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Table 3 Hazard ratios for risk of secondary cerebral ischemia and rebleeding after aneurysmal subarachnoid hemorrhage according to genotype




FV Leiden Secondary cerebral ischemia No secondary cerebral ischemia
GG 45 (23.0%) 151 (77.0%) 1 (reference) 1 (reference)
GA and AA 4 (36.4%) 7 (63.6%) 1.8 (0.6–4.9) 1.8 (0.6–5.0)
Rebleeding No rebleeding
GG 26 (13.2%) 171 (86.8%) 1 (reference)
GA and AA 1 (9.1%) 10 (90.9%) 0.6 (0.1–4.5) NA
Prothrombin G20210A Secondary cerebral ischemia No secondary cerebral ischemia
GG 48 (24.0%) 152 (76.0%) 1 (reference) 1 (reference)
GA and AA 1 (14.3%) 6 (85.7%) 0.5 (0.1–3.9) 0.5 (0.1–3.9)
Rebleeding No rebleeding
GG 27 (13.4%) 174 (86.6%) 1 (reference)
GA and AA 0 (0%) 7 (100%) 0.7 (0.1–5.4) NA
MTHFR C677T Secondary cerebral ischemia No secondary cerebral ischemia
CC and CT 47 (25.4%) 138 (74.6%) 1 (reference) 1 (reference)
TT 2 (9.1%) 20 (90.9%) 0.4 (0.1–1.5) 0.4 (0.1–1.5)
Rebleeding No rebleeding
CC and CT 22 (11.9%) 163 (88.1%) 1 (reference)
TT 4 (18.2%) 18 (81.8%) 0.6 (0.2–1.7) NA
FXIII A Val34Leu Secondary cerebral ischemia No secondary cerebral ischemia
ValVal 30 (24.62%) 92 (75.4%) 1 (reference) 1 (reference)
ValLeu and LeuLeu 18 (20.9%) 68 (79.1%) 0.9 (0.5–1.6) 0.9 (0.5–1.6)
Rebleeding No rebleeding
ValVal 14 (11.4%) 109 (88.6%) 1 (reference)
ValLeu and LeuLeu 14 (16.3%) 72 (83.7%) 1.2 (0.5–2.6) NA
FXIII A Tyr204Phe Secondary cerebral ischemia No secondary cerebral ischemia
TyrTyr 44 (23.4%) 144 (76.6%) 1 (reference) 1 (reference)
TyrPhe and PhePhe 4 (21.1%) 15 (78.9%) 0.9 (0.3–2.4) 0.9 (0.3–2.4)
Rebleeding No rebleeding
TyrTyr 27 (14.3%) 162 (85.7%) 1 (reference)
TyrPhe and PhePhe 1 (5.3%) 18 (94.7%) 0.3 (0.0–2.5) NA
FXIII A Pro564Leu Secondary cerebral ischemia No secondary cerebral ischemia
ProPro 31 (27.2%) 83 (72.8%) 1 (reference) 1 (reference)
ProLeu and LeuLeu 17 (21.3%) 63 (78.8%) 0.8 (0.4–1.4) 0.8 (0.4–1.4)
Rebleeding No rebleeding
ProPro 12 (10.5%) 102 (89.5%) 1 (reference)
ProLeu and LeuLeu 14 (17.5%) 66 (82.5%) 1.8 (0.8–4.2) NA
FXIII B His95Arg Secondary cerebral ischemia No secondary cerebral ischemia
HisHis 33 (21.9%) 118 (78.1%) 1 (reference)
HisArg and ArgArg 14 (31.1%) 31 (68.9%) 1.5 (0.8–2.8) 1.6 (0.8–2.9)
Rebleeding No rebleeding
HisHis 18 (11.8%) 134 (88.2%) 1 (reference)
HisArg and ArgArg 8 (17.8%) 37 (82.2%) 1.1 (0.4–2.9) NA
*Adjusted for clinical condition on admission and amount of blood on initial CT scan.
CI = confidence interval; NA = not applicable
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G20210A and the subunit Tyr204Phe factor XIII polymor-
phisms showed an increased risk of aneurysmal SAH, but
these differences did not reach statistical significance. Carriers
of the factor V Leiden (factor V G1691A), MTHFR C677T,
subunit A Val34Leu and Pro564Leu factor XIII polymor-
phisms did not have a higher risk of aneurysmal SAH.
Table 3 shows the HR for the risk of secondary cerebral
ischemia and rebleeding according to genotype. A clear
relation with the risk of secondary cerebral ischemia and of
rebleeding could not be established for any of these genetic
variants. However, for some polymorphisms, an association
was observed, although with wide confidence intervals.
Notably, for the factor V Leiden polymorphism that has
been proven to be associated with an increased risk of
thrombosis in previous studies [5], we found a moderately
increased risk of secondary cerebral ischemia (crude HR
1.8, 95% CI 0.6–4.9 and adjusted HR 1.8, 95% CI 0.6–5.0)
and an opposite lower risk of rebleeding (HR 0.6, 95% CI
0.1–4.5), although this did not reach statistical significance.
Discussion
This study was performed to analyze whether genes
influencing coagulation are associated with the occurrence
of aneurysmal SAH and with the risk of secondary cerebral
ischemia and rebleeding in patients with aneurysmal SAH.
Polymorphisms in the factor V Leiden, prothrombin
G20210A, MTHFR C677T, subunit AVal34Leu, Tyr204Phe
and Pro564Leu factor XIII and subunit B His95Arg factor
XIII were investigated.
With regard to the risk of aneurysmal SAH, we found
that aneurysmal SAH patients are more often carriers of the
subunit B His95Arg factor XIII polymorphism compared to
controls. This suggests that carriers of the subunit B
His95Arg factor XIII polymorphism have an increased risk
of aneurysmal SAH. As yet not much is known about the
His95Arg polymorphism in the factor XIII subunit B. One
study suggested the Arg95 variant to be associated with an
increased risk of thrombosis in combination with an
increased factor XIII subunit B dissociation [18]. Our
finding that the His95Arg factor XIII subunit B polymor-
phism is associated with an increased risk of aneurysmal
SAH is not consistent with the previous observation of an
increased risk of thrombosis [18]. Further studies investi-
gating the influence of this variant on the risk of thrombosis
and bleeding are needed. Ideally, we would have analyzed
data on the coagulation system and the overall thrombosis
and bleeding risk in our patient group and related those data
to the polymorphisms studied. Unfortunately, we do not
have these data for our studied patients.
On analyzing the association of genes influencing
coagulation with the occurrence of secondary cerebral
ischemia and rebleeding in patients with aneurysmal SAH,
no unequivocal, large effects could be demonstrated. This
may be explained by the fact that our study population was
relatively small. However, larger studies are difficult to
perform as these should include approximately over 1,000
patients to demonstrate the small effects (HR of 1.5 or
smaller) of the coagulation factors.
Our findings do suggest that, consistent with the increased
risk of thrombosis of the factor V Leiden polymorphism [5],
factor V Leiden is associated with an increased risk of
secondary ischemia and an opposite decreased risk of
rebleeding in patients with aneurysmal SAH. These results
should be interpreted with caution as the 95% CIs were wide
for all the HR calculated in this study.
Aneurysmal SAH patients who died soon after admission
could not be included in the present study because they could
not be asked to participate. Our results therefore apply to a
population of patients who survived the initial hours after the
hemorrhage. Not including these patients may have biased our
results as some of these patients may have died because of
early rebleeding within hours of the initial hemorrhage [10,
13], leading to an under representation of patients with
rebleeding in our study.
The results of this study suggest that genetic factors are
involved in coagulation in the occurrence of aneurysmal
SAH as we found evidence that carriers of the subunit B
His95Arg factor XIII polymorphism are at increased risk.
Larger studies should confirm our results. For the other
studied polymorphisms involved in coagulation, no associ-
ation with the occurrence of aneurysmal SAH or with the
occurrence of secondary cerebral ischemia or rebleeding
after aneurysmal SAH could be demonstrated.
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